Hemophilia B

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA ALERT
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
FDA ALERT
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
HIV
HIV
FDA Approves Once-Daily HIV Drug, New Option for Asthma
11/06/2015
The FDA has approved a new, daily, fixed-dose combination therapy for HIV treatment, and a new add-on treatment for severe, poorly-controlled asthma.
11/06/2015
Melanoma
Melanoma
FDA Approves Options for Melanoma, Soft Tissue Sarcomas
10/28/2015
The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.
10/28/2015
Melanoma
Melanoma
FDA Approves Options for Melanoma, Soft Tissue Sarcomas
10/28/2015
The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.
10/28/2015
Melanoma
Melanoma
FDA Approves Options for Melanoma, Soft Tissue Sarcomas
10/28/2015
The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.
10/28/2015
Cancer
Cancer
FDA: New Options for Hyperkalemia, Pancreatic Cancer, Rare Bleeding Disorder
10/22/2015
The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.
10/22/2015
Cancer
Cancer
FDA: New Options for Hyperkalemia, Pancreatic Cancer, Rare Bleeding Disorder
10/22/2015
The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.
10/22/2015
Cancer
Cancer
FDA: New Options for Hyperkalemia, Pancreatic Cancer, Rare Bleeding Disorder
10/22/2015
The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.
10/22/2015